Aktis Oncology (NASDAQ:AKTS) Stock Rating Upgraded by Raymond James Financial

Aktis Oncology (NASDAQ:AKTS) was upgraded by Raymond James Financial to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

AKTS has been the subject of several other reports. William Blair assumed coverage on shares of Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating for the company. Weiss Ratings lowered shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, June 9th. Finally, HC Wainwright increased their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Aktis Oncology Stock Up 9.4%

NASDAQ:AKTS opened at $22.63 on Monday. Aktis Oncology has a 1-year low of $14.72 and a 1-year high of $29.16. The business has a 50-day simple moving average of $19.40.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The company had revenue of $1.87 million for the quarter. Analysts predict that Aktis Oncology will post -1.62 earnings per share for the current fiscal year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.